Angle has entered a research collaboration with Myriad Genetics to co-develop liquid biopsy assays leveraging Angle’s Parsortix platform for circulating tumor cell (CTC) capture. The partnership aims to compare CTC-derived DNA with tissue biopsy samples using Myriad's established assays. Angle's semiautomated Parsortix system isolates rare cells from blood samples based on physical properties and has existing collaborations with AstraZeneca and BioView. This effort aligns with expanding dual CTC and circulating tumor DNA analyses to enhance cancer diagnostics.